RNF183 Inhibitors

MG132 and Lactacystin impair the proteasome's ability to degrade proteins, which could stabilize proteins that RNF183 tags for degradation, thus indirectly inhibiting RNF183's function. Bortezomib, another proteasome inhibitor, shares this mode of action. In contrast, Chloroquine and FCM elevate the pH within lysosomes, which may interfere with RNF183's ability to direct proteins to lysosomal degradation.

The role of RNF183 in autophagy, a process for recycling cellular components, can be influenced by compounds like 3-MA, LY294002, and Wortmannin, which inhibit early stages of autophagosome formation or block the PI3K pathway involved in autophagy regulation. These inhibitors, by modulating autophagy, can indirectly alter the turnover of cellular components that RNF183 might regulate. Furthermore, kinases that signal through pathways such as MEK, JNK, and p38 MAPK are targeted by PD98059, SP600125, and SB203580, respectively. These inhibitors can affect the downstream signaling cascades, which could be part of the regulatory network within which RNF183 operates. Lastly, Z-VAD-FMK, as a pan-caspase inhibitor, can influence apoptotic processes, potentially affecting the degradation or turnover of proteins that interact with RNF183.